Insulin glargine overdose
Fatma Sarı Doğan1★, Özge Ecmel Onur2, Arzu Denizbaşı Altınok2, Özlem Güneysel3★ Corresponding author
- 1Department of Emergency Medicine, Goztepe Training and Research Hospital, Istanbul, Turkey.
- 2Marmara University School of Medicine, Istanbul, Turkey.
- 3Emergency Medicine Clinic, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Emergency Medicine Clinic Istanbul, Turkey.
CORRESPONDENCE
Fatma Sarı Doğan
Department of Emergency Medicine, Goztepe Training and Research Hospital, Istanbul, Turkey.
Volume 3, Issue 4 · pp. 333–335 · PUBLISHED 2011 · DOI: 10.4103/0976-500X.103694
View on J Pharmacol. Pharmacother. original site ↗
ABSTRACT
Insulin glargine is a long acting novel recombinant human insulin analogue indicated to improve glycemic control, in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. The time course of action of insulins including insulin glargine may vary between individuals and/or within the same individual. Insulin glargine is given as a 24-h dosing regimen and has no documented half-life or peak effect. Hypoglycemia is the most common adverse effect of insulin, including insulin glargine. As with all insulins, the timing of hypoglycemia may differ among various insulin formulations. We present a case of a 76-year-old male insulin-dependent diabetic patient with refractory hypoglycemia secondary to an intentional overdose of insulin glargine. We would like to highlight the necessity of prolonging IV glucose infusion, for a much longer period than expected from pharmacokinetic properties of these insulin analogues after intentional massive overdose.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Doğan, F. S., Onur, Ö. E., Altınok, A. D., & Güneysel, Ö. (2011). Insulin glargine overdose. Journal of Pharmacology and Pharmacotherapeutics, 3(4), 333–335. https://doi.org/10.4103/0976-500X.103694